Novel Genotoxic Impurities in the First-Line Oral Anticoagulant Drug, Apixaban: Computational Toxicological...

Area of Science:

• Pharmaceutical Chemistry
• Analytical Chemistry
• Toxicology

Background:

• Apixaban, a direct factor Xa inhibitor, is a key oral anticoagulant for thromboembolic conditions.
• Manufacturing apixaban requires stringent testing for potential genotoxic impurities due to its chemical structure.
• International Council for Harmonisation (ICH) M7 guidelines mandate setting impurity limits to minimize patient exposure.

Purpose of the Study:

• To establish acceptable limits for three novel genotoxic impurities (F, G, H) of apixaban through computational toxicological evaluation.
• To develop and validate a highly sensitive liquid chromatography-tandem mass spectrometry (LS-MS/MS) method for quantifying these impurities.

Main Methods:

• Computational toxicology was employed to determine impurity limits.
• A gradient elution method using a C18 column with an acetate buffer and acetonitrile mobile phase was developed.
• Quantification of impurities F, G, and H was achieved using multi-response monitoring in mass spectrometry.

Main Results:

• Acceptable limits for apixaban genotoxic impurities F, G, and H were established.
• A sensitive and validated LS-MS/MS method was successfully developed for impurity quantification.
• The analytical method demonstrated suitability for routine quality control during apixaban manufacturing.

Conclusions:

• The study successfully set regulatory limits for novel genotoxic impurities in apixaban.
• The validated LS-MS/MS method provides a reliable tool for ensuring the safety and quality of apixaban.
• Adherence to these findings supports patient safety by controlling potential genotoxic contaminants.